SGYP Share Price

Open 2.71 Change Price %
High 2.83 1 Day 0.03 1.11
Low 2.71 1 Week 0.00 0.00
Close 2.73 1 Month -0.36 -11.65
Volume 3712902 1 Year -2.56 -48.39
52 Week High 7.15
52 Week Low 2.56
SGYP Important Levels
Resistance 2 2.84
Resistance 1 2.80
Pivot 2.76
Support 1 2.66
Support 2 2.62
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP)

SGYP Technical Analysis 5
As on 31st Oct 2017 SGYP Share Price closed @ 2.73 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.39 & Strong Sell for SHORT-TERM with Stoploss of 2.91 we also expect STOCK to react on Following IMPORTANT LEVELS.
SGYP Target for November
1st Target up-side 3.27
2nd Target up-side 3.65
3rd Target up-side 4.03
1st Target down-side 2.19
2nd Target down-side 1.81
3rd Target down-side 1.43
SGYP Other Details
Segment EQ
Market Capital 240850608.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.synergypharma.com
SGYP Address
SGYP
420 Lexington Avenue
Suite 2012
New York, NY 10170
United States
Phone: 212-297-0020
Fax: 212-297-0019
SGYP Latest News
Interactive Technical Analysis Chart Synergy Pharmaceuticals, Inc. ( SGYP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Synergy Pharmaceuticals, Inc.
SGYP Business Profile
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�s active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors. As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor.